On November 6, at the 7th China International Import Expo (hereinafter referred to as "CIIE"), Novo Nordisk held a press conference and announced that the world's first weekly insulin formulation, Novozymes® (insulin Efficacy Injection), which was exhibited for the first time at this CIIE, will be commercially launched in China at the end of November 2024 for the treatment of type 2 diabetes in adults, ushering in the era of weekly insulin treatment.

Professor Peng Yongde, head of the Department of Endocrinology and Metabolism at the First People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine, said: "Insulin therapy is still an indispensable and important cornerstone in the diabetes management pathway. As a key component, basal insulin strives to better meet clinical treatment needs to help patients start treatment in a timely manner, improve treatment compliance, increase treatment continuity, and improve patient satisfaction."

Insulin "from day to week" innovative breakthrough, helping diabetic patients achieve blood sugar standards

100 years ago, the discovery of insulin turned diabetes from an incurable disease into a controllable disease. In the past 100 years, insulin preparations have experienced great development, among which prolonging the duration of action of basal insulin through various methods has always been a hot spot for research and development innovation.

Zhang Kezhou, corporate vice president of pharmaceutical and quality department of Novo Nordisk Greater China, said: "Novo Nordisk has extensive experience and multiple successful products in using fatty acid acylation technology to extend the half-life of peptide drugs. Novo Nordisk® is based on fatty acids Acylation technology can combine with albumin in a strong and reversible manner. The half-life in the human body is as long as 196 hours. Within a one-week dosing interval, the hypoglycemic effect of insulin Eco is evenly distributed. At clinically relevant doses, the hypoglycemic effect lasts as long as Covering one week, a century-old breakthrough in basal insulin from day to week has been achieved.”

Professor Peng Yongde said that the ONWARDS series of global phase 3 clinical trials of Insulin Eco included a total of 3,765 patients with type 2 diabetes, which verified its good hypoglycemic efficacy and safety. Compared with basal daily insulin preparations, it can help more patients with type 2 diabetes achieve the treatment goal of glycated hemoglobin <7% and no hypoglycemia, and significantly improve patient treatment satisfaction and compliance.

With simultaneous innovation at home and abroad, CIIE Baby will achieve a triple jump in growth

At the same time, NovoStage® is also the first implementation result of Novo Nordisk's "China Co-Creation" project. It is the first time that innovative drugs at home and abroad are approved almost "without time difference" within half a year, allowing Chinese patients to benefit from global innovative drugs earlier. At the 6th CIIE last year, it was exhibited in the form of clinical research documents. In just one year, it has changed from documents to exhibits, achieving a "triple jump" from exhibits to commodities.

Zhang Kezhou, Corporate Vice President of Pharmaceuticals and Quality, Novo Nordisk Greater China, introduced: "The CIIE has witnessed the growth of the 'China Co-Creation' project. In 2019, the 'China Co-Creation' project was launched with the goal of achieving simultaneous clinical trials and approvals of innovative drugs in China and around the world. In 2020, we announced at the CIIE that the project had entered Phase 2.0; this year at the CIIE, we brought the first results. The realization of 'China Co-Creation, World Synchronization' by Novostage® reflects the acceleration of innovation brought about by the reform of the drug review and approval system, as well as the improvement of China's clinical research capabilities. It also witnesses the leap of China's clinical research innovation from 'following to leading'."

Zhou Xiaping, Global Senior Vice President and President of Novo Nordisk Greater China, said: "For a century, Novo Nordisk has been based in and continuously deepened the field of diabetes treatment, leading scientific breakthroughs and expanding the accessibility of the company's drugs. Every step we take on the road of innovation is for patients to take the next step with hope. This year marks the 30th anniversary of the establishment of Novo Nordisk China. We are very proud that this year has achieved the simultaneous approval of insulin weekly preparations at home and abroad, which is another step forward in improving the happiness of patients' lives." She also pointed out, "After seven years of participating in the CIIE, Novo Nordisk has entered the Chinese market with a number of CIIE babies from the four-leaf clover. In the future, we will continue to accelerate innovation, deepen cooperation, and benefit more patients."

About Novo Nordisk: Novo Nordisk was founded in 1923 and is a leading global biopharmaceutical company headquartered in Denmark. Building on a century-long heritage in the field of diabetes, our mission is to drive change and work together to defeat serious chronic diseases. To achieve this goal, we lead scientific breakthroughs, expand access to the company's medicines, and are committed to preventing and ultimately curing diseases. Novo Nordisk has approximately 69,000 employees in 80 countries and regions around the world, providing products and services to approximately 170 countries and regions around the world.

https://news.yaozh.com/archive/44497.html